Takara Bio Licenses Gene Mutation Patent to InVivoScribe Technologies | GenomeWeb
NEW YORK (GenomeWeb News) - Takara Bio has licensed to InVivoScribe Technologies its patent for detecting the mutations of FMS-like tyrosine kinase 3 genes, Takara Bio said today.
 
Under the agreement, InVivoScribe will receive an exclusive license to use the patent worldwide, except in Japan. The company will be allowed to develop, manufacture, and sell a reagent for detecting FLT3 gene mutations. It can also sublicense the patent to others.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.